Reference : Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Cha...
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Systems Biomedicine
http://hdl.handle.net/10993/42698
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
English
Koncina, Eric mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Haan, Serge mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Rauh, Stefan [Centre Hospitalier Emile Mayrisch > Department of Oncology]
Letellier, Elisabeth mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
30-Jan-2020
Cancers
MDPI AG
Yes
International
2072-6694
Switzerland
[en] colorectal cancer ; biomarkers ; molecular markers ; early stage CRC ; gene signature ; clinical transition
[en] Colorectal cancer (CRC) is a leading cause of death among cancer patients. This heterogeneous disease is characterized by alterations in multiple molecular pathways throughout its development. Mutations in RAS, along with the mismatch repair gene deficiency, are currently routinely tested in clinics. Such biomarkers provide information for patient risk stratification and for the choice of the best treatment options. Nevertheless, reliable and powerful prognostic markers that can identify “high-risk” CRC patients, who might benefit from adjuvant chemotherapy, in early stages, are currently missing. To bridge this gap, genomic information has increasingly gained interest as a potential method for determining the risk of recurrence. However, due to several limitations of gene-based signatures, these have not yet been clinically implemented. In this review, we describe the different molecular markers in clinical use for CRC, highlight new markers that might become indispensable over the next years, discuss recently developed gene expression-based tests and highlight the challenges in biomarker research.
Fondation Cancer (F1R-LSC-PAU-13HY2C), Proof of Concept grant (PoC18/12554295) through the FNR, Foundation Vera Nijs and Jens Erik Rosborg
Researchers
http://hdl.handle.net/10993/42698
10.3390/cancers12020319

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Koncina et al., 2020.pdfPublisher postprint317.17 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.